Clementia Pharmaceuticals Inc., of Montreal, said the Journal of Bone and Mineral Research has published online a study describing palovarotene's beneficial effects on spontaneous heterotopic ossification, mobility and skeletal growth in mouse models of fibrodysplasia ossificans progressiva (FOP).